TP53 and cancer: This competition leads to the inhibition of mouse double minute 2 homolog (MDM2) auto-ubiquitination and, subsequently, the promotion of MDM2-mediated ubiquitination and degradation of p53, thereby inhibiting apoptosis and promoting cancer development.